Garland Jason K 4

What Happened
Jason K. Garland, Chief Financial Officer of Repligen Corporation (RGEN), received equity compensation on March 5, 2026 consisting of 7,751 restricted stock units (RSUs) and 8,315 derivative awards reported as stock options. Both grants were reported at $0.00 (i.e., no cash paid by the insider). The RSUs represent the contingent right to receive one share per unit and will settle only in shares. These are compensation grants (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 23, 2026. (This filing date is 18 days after the grant date and appears later than the typical two-business-day Form 4 reporting window.)
• Grants: 7,751 RSUs (reported as shares acquired @ $0.00) and 8,315 derivative awards (reported @ $0.00).
• Vesting:
  • RSUs: Vest in equal annual installments over three years beginning on the first anniversary of the grant (per footnote F1).
  • Options/derivative awards: One‑third vests annually on March 5 of 2027, 2028 and 2029 (per footnote F2).
• Shares owned after the transaction: Not disclosed in the provided filing summary.
• Transaction code: A = Award/Grant. These are compensation grants, not purchases/sales; no immediate sale or cashless exercise was reported.

Context

• These awards are part of executive compensation and do not involve an immediate market purchase or sale of shares; they vest over time and will convert to stock (RSUs settle only in shares; options vest per schedule). Such grants are routine for executives and reflect compensation, not a direct buy/sell signal. The delayed filing may be noted by investors but does not by itself indicate trading intent.